Dr. Philippe Dro is currently chairman, chief executive officer and director of the board at Luciole Medical (Zürich, Switzerland), CHAIRMAN OF LIMMATECH BIOLOGICS (ZÜRICH SWITZERLAND), member of the board at Themis Bioscience GmbH, (Austria) as well as Omics SA Bioinformatics (France), a BIOINFORMATIC COMPANY. He WAS CEO AND DIRECTOR at Glycovaxyn AG (ZÜRICH, Switzerland) WHICH WAS ACQUIRED BY GSK IN 2015. HE SERVED IN THE BOARD OF Aleva Therapeutics SA (Switzerland), Spinevision SA (France), Antares Pharma Ltd (USA), and SkyePharma Ltd (USA).
Dr. Philippe Dro ALSO served as a chairman and chief executive officer at ENDOART SA (Lausanne, Switzerland) ACQUIRED BY ALLERGAN IN 2007 AND as a chief financial officer/chief operating officer at Axovan AG (Basel, Switzerland), and president & chief operating officer. He has a PHARMD FROM GRENOBLE SCHOOL OF PHARMACY (FRANCE) and a MBA both from Ecole Supérieure de Commerce de Lyon (France) and Cranfield School of Management (UK).
Gerd Zettlmeissl has been working in various R&D and General Management positions in the biopharmaceutical and vaccine industry since 1985. His last positions were Managing Director of Chiron Behring, a leading vaccine manufacturer in Germany, and until May 2011, Chief Executive Officer of Intercell, in Austria. During his career, he made major contributions to the discovery, development and registration of a number of biologicals and vaccines. He currently serves as Non-Executive Director of Aeras, a non-profit organization developing tuberculosis vaccines, and of various biotech companies. Gerd holds a doctoral degree in biochemistry of the University of Regensburg and did a post-doctoral fellowship at the Institute Pasteur Paris in virology between 1983 and 1985.
Mounia Chaoui is Venture Partner at Ventech and General partner at Turenne capital in charge of Venture and Growth Capital in healthcare totaling 110 Mio EUR since 2013. Prior to this, Mounia has been a Life Science investor within Ventech (since 2001), Inserm Transfert Initiative (2012) and Atlas Venture (1998 to 1999). She has been on the board of Actogenix (sold to Intrexon), Biovex (sold to Amgen for up to 1 billion USD), Covagen (sold toJ&J), EyeGate (now EYGT), Funxional Therapeutics (sold to Boehringer Ingelheim), Prosonix (sold to Circassia), Tigenix (now EUR:TIG) and SCYNEXIS (SCYX). Besides Themis, Mounia is on the board of Alize Pharma, Didactic, DNA therapeutics, EyeGate, EYETECHCARE, JRI and SEBBIN. Mounia holds a PhD in Biophysics and an Engineering degree from Ecole Centrale Paris.
Regina Hodits is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Themis, Rigontec, Middle Peak Medical, AYOXXA, and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GlaxoSmithKline’s Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.
Further stations of her career were Atlas Venture and Apax Partners, for which she served on several Boards, including Bicycle Therapeutics, F-star (partly acquired by BMS), U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, (acquired by SciClone, NASDAQ SCLN). Regina Hodits studied chemical engineering in Vienna and holds a Ph.D. in biochemistry. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey.
Ralf Kunzmann is Managing Director of aws Fondsmanagement GmbH and aws Founders Fund (aws Gründerfonds), Austria’s most active Venture Capital Fund. Before joining aws in 2013 he was many years responsible for the international private equity activities of UniCredit Bank Austria Group and held numerous operational management functions as Managing Director and CFO at portfolio companies. Prior to that, he worked with KPMG in financial advisory services with specialization in corporate finance. After completing his studies in business administration, Ralf started his career in the healthcare industry in Investment Controlling and Corporate Development. Ralf is lecturer and author of numerous publications in the field of business acquisition.
After ten years at academia, Jean Paul Prieels started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities in Rixensart, Belgium. He retired as Senior Vice President of Research & Development at GlaxoSmithKline Biologicals in 2011. His career spans from basic research to applied research and product development. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix and Synflorix. Today he is involved as director or member of the advisory board in biotech and non-profit organizations. Jean Paul Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles, Belgium.
Mr. Rockman started his career in J.P. Morgan’s investment banking division, where he spent more than 10 years advising and raising capital for universities, research institutions and other social enterprises. After working closely with the Bill & Melinda Gates Foundation to structure and launch GHIF, he left J.P. Morgan in 2014 to join the fund’s investment management team. He currently serves on the boards of a number of companies focused on innovative technologies for public health, including EuBiologics (206650:KOSDAQ), Tribendimidine Finance Company and IanTech. Mr. Rockman holds an AB from the Woodrow Wilson School of Public and International Affairs at Princeton University.
Maximilien Fournier-Sourdille is Associate specialized in healthcare investments in the Venture Capital team at Omnes Capital. Prior to that, Maximilien co-founded FeetMe, a medical device company that allows continuous monitoring and analysis of patient’s gait suffering from neurological disorders. He developed the product from strategy definition to commercial launch in Europe. He created and lead a cross functional team in charge of technical, clinical and regulatory affairs.
Besides Themis, Maximilien represents Omnes Capital on the boards of Enterome, Eye Tech Care and Gecko Biomedical. Maximilien graduated from Ecole Polytechnique and holds a MS in Bioengineering from the University of California Los Angeles (ULCA).